{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361418520105656960.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1365-2893.2005.00695.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2893.2005.00695.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2893.2005.00695.x"}}],"dc:title":[{"@value":"Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p><jats:bold>Summary. </jats:bold> Acute hepatitis B progresses to liver failure with the need of liver transplantation in about 1% of cases. We treated patients with severe acute or fulminant hepatitis B with lamivudine in an attempt to prevent hepatitis B virus (HBV) reinfection after potential liver transplantation. Since September 2000, 17 patients with severe acute or fulminant HBV infection were treated with 100 or 150 mg lamivudine daily once we had evidence for a severe course as indicated by an INR >2.0. These were compared to a historic control from our unit and to external patients. Fourteen of the 17 patients (82.4%) survived with full recovery without liver transplantation. All these 14 individuals cleared HBsAg on lamivudine within less than 6 months. Twelve patients recovered quickly as indicated by a normalized prothrombin time within 1 week while two patients had a more prolonged course. None of the patients showed an adverse event. Three patients requiring transplantation despite lamivudine therapy had more advanced disease on admission, of whom one had additionally ingested paracetamol (acetaminophen) while the second was already HBV‐DNA negative by polymerase chain reaction on admission. The lamivudine treated patients had significant higher frequency of survival without liver transplantation 82.4 <jats:italic>vs</jats:italic> 20% (4/20) in the historic control (<jats:italic>P</jats:italic> < 0.001). Similar data were derived from external centres using lamivudine (15/20, 75%). Lamivudine is safe in patients with severe acute or fulminant hepatitis B, leading to fast recovery with the potential to prevent liver failure and liver transplantation when administered early enough.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381418520105656964","@type":"Researcher","foaf:name":[{"@value":"H. L. Tillmann"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656960","@type":"Researcher","foaf:name":[{"@value":"J. Hadem"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656963","@type":"Researcher","foaf:name":[{"@value":"L. Leifeld"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656832","@type":"Researcher","foaf:name":[{"@value":"K. Zachou"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656966","@type":"Researcher","foaf:name":[{"@value":"A. Canbay"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656965","@type":"Researcher","foaf:name":[{"@value":"C. Eisenbach"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656962","@type":"Researcher","foaf:name":[{"@value":"I. Graziadei"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656967","@type":"Researcher","foaf:name":[{"@value":"J. Encke"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656834","@type":"Researcher","foaf:name":[{"@value":"H. Schmidt"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656837","@type":"Researcher","foaf:name":[{"@value":"W. Vogel"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656961","@type":"Researcher","foaf:name":[{"@value":"A. Schneider"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656968","@type":"Researcher","foaf:name":[{"@value":"U. Spengler"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656969","@type":"Researcher","foaf:name":[{"@value":"G. Gerken"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656836","@type":"Researcher","foaf:name":[{"@value":"G. N. Dalekos"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656833","@type":"Researcher","foaf:name":[{"@value":"H. Wedemeyer"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520105656835","@type":"Researcher","foaf:name":[{"@value":"M. P. Manns"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13520504"},{"@type":"EISSN","@value":"13652893"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/13520504"}],"prism:publicationName":[{"@value":"Journal of Viral Hepatitis"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2006-02-20","prism:volume":"13","prism:number":"4","prism:startingPage":"256","prism:endingPage":"263"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2893.2005.00695.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2893.2005.00695.x"}],"createdAt":"2006-02-20","modifiedAt":"2023-10-14","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576118673180672","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The Combination of Nucleotide Analog Therapy and Steroid Pulse Therapy for Acute HBV Infection Effectively Promotes HBV Clearance"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204870909184","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Lamivudine Treatment Improves the Prognosis of Fulminant Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679772068224","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"An elderly case of tuberculous pleuritis with the onset of refractory pleural effusion after acute hepatitis B"},{"@language":"ja","@value":"高齢者のB型急性肝炎後に難治性胸水として発症した結核性胸膜炎の1例"},{"@value":"症例報告 高齢者のB型急性肝炎後に難治性胸水として発症した結核性胸膜炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク コウレイシャ ノ Bガタ キュウセイ カンエン ゴ ニ ナンチセイ キョウスイ ト シテ ハッショウ シタ ケッカクセイ キョウマクエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390297659208940928","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A descriptive analysis of acute viral hepatitis using a database with electronic medical records and claims data"}]},{"@id":"https://cir.nii.ac.jp/crid/1390845712966628480","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Early Combination Therapy with Corticosteroid and Nucleoside Analogue Induces Rapid Resolution of Inflammation in Acute Liver Failure due to Transient Hepatitis B Virus Infection"},{"@value":"Early combination therapy with corticosteroid and nucleoside analog induces rapid resolution of inflammation in acute liver failure due to transient hepatitis B virus Infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1365-2893.2005.00695.x"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.47.1061_references_DOI_DQY0ob7YSTuSnDw4MIGCIWKFlJP"},{"@type":"CROSSREF","@value":"10.37737/ace.23014_references_DOI_DQY0ob7YSTuSnDw4MIGCIWKFlJP"},{"@type":"CROSSREF","@value":"10.2957/kanzo.55.267_references_DOI_DQY0ob7YSTuSnDw4MIGCIWKFlJP"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_DQY0ob7YSTuSnDw4MIGCIWKFlJP"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.9670-17_references_DOI_DQY0ob7YSTuSnDw4MIGCIWKFlJP"},{"@type":"CROSSREF","@value":"10.3390/gastroent13010001_references_DOI_DQY0ob7YSTuSnDw4MIGCIWKFlJP"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_DQY0ob7YSTuSnDw4MIGCIWKFlJP"}]}